Connecting Psychiatry - Expert community for all mental health professionals

Invega (paliperidone), Son of Risperdal (risperidone), Wins FDA Okay for Schizophrenia

(PSYCHIATRIC TIMES) - MedPage Today Action Points

ROCKVILLE, Md., Dec. 20 -- The FDA today approved Invega (paliperidone) for treatment of acute schizophrenia.

Although the drug contains an active substance never before approved by the FDA, that substance is an active metabolite of an old drug, the atypical antipsychotic Risperdal (risperidone), which is marketed for treating schizophrenia.

The effectiveness of Invega in the acute treatment of schizophrenia was established in three six-week placebo-controlled trials conducted in North America, Europe and Asia.

For full article, please visit:

Views: 6


You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds

psychiatryRounds Social Media


CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2020   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service